Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial BOSTON, October 8, 2026 – Life Biosciences (“Life Bio”), ...

BOSTON, October 1, 2026 – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced that the company will present ...

BOSTON, August 10, 2026 – Life Biosciences (“Life Bio”), a clinical-stage biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced the appointment ...

Lead epigenetic restoration therapy enters the clinic for glaucoma and NAION, targeting a root cause of age-related vision loss BOSTON, June 9, 2026 — Life Biosciences, Inc. (“Life Bio”), a ...

Funding to support the Phase 1 clinical trial of ER-100 in optic neuropathies and further investigation of new candidates from the company’s Partial Epigenetic Reprogramming platform BOSTON, April 8, ...

Tristan Edwards, the co-founder of Life Biosciences, is the co-founder and CEO of Entheos Labs, a Boston-based biotech created within Massachusetts General Hospital (MGH) that treats mental health ...

Life Biosciences’ lead candidate, ER-100 (AAV2-OSK), is in Phase 1/2A clinical trials for optic neuropathies. This is the first-ever epigenetic restoration candidate approved for clinical trials, and ...

October 8, 2026 Eye Cells May Have Been Rejuvenated for the First Time in People TIME July 24, 2026 ER-100 Enters Optic Neuropathy Trial The Ophthalmologist June 18, 2026 Longevity medicine’s ...

BOSTON, January 28, 2026 – Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced ...

These data, along with additional ER-100 preclinical data from a nonhuman primate model of NAION demonstrating clear restoration of methylation patterns with functional enrichment of neuronal ...

Collaboration in Singapore aims to further expand the broad potential of Life Bio’s Partial Epigenetic Reprogramming Platform as part of Life Bio’s global mission to transform how people age BOSTON, ...

BOSTON, January 27, 2025 – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the ...